Get ready to negotiate, payers: Amgen has its PCSK9 outcomes data. In a long-awaited trial, Repatha cut heart attack risks by 27% and stroke risks by 21%. Will…

Sen. Bernie Sanders and Rep. Elijah Cummings have 'serious questions' for the FDA after its approval of Marathon's controversial Duchenne med…

AstraZeneca’s Lynparza honed its edge in ovarian cancer on Tuesday, just in time to help preserve its lead in the marketplace.

Plenty of companies have talked about—and even dabbled in—newfangled pricing schemes. But Novartis is about to seriously raise the bar with new cancer-fighter…

In response to tough new comments on pricing from a Gilead Sciences exec, Express Scripts is fighting back.

With new meds and biosimilars pouring into the dermatology market, we’re looking at a shakeup ahead. Here's your cheat sheet on the top data rolled out at…

Drugmakers spend big money and lots of time crafting the names of their new products. In the end, after all that work, they’re prime candidates for spoofing.…

As Synergy's launch for constipation med Trulance approaches, it's getting ready to make waves in the market with on-par pricing and a salesforce of…

Thanks to some crafty payer negotiating from GSK, even if Advair generics win approval, it may be a while before they gain serious traction, even if it wins…

Launches